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ABSTRACT
NRG1 fusions were recently reported as a new molecular feature of Invasive 
Mucinous Adenocarcinoma (IMA) of the lung. The NRG1 chimeric ligand acts as a 
strong inductor of phosphorylation and tyrosine kinase activity of the ErbB2/ErbB3 
heterodimer, thus enhancing the PI3K–AKT/MAPK pathways. The NRG1 fusions were 
widely investigated in Asian IMA cohorts, whereas just anecdotal information are 
available about the occurrence of NRG1 fusions in IMA Caucasian population. 
Here we firstly explored a large Caucasian cohort of 51 IMAs and 34 non-
IMA cases for the occurrence of NRG1 rearrangements by fluorescent in situ 
hybridization (FISH) and RNA target sequencing. FISH results were correlated to 
the immunohistochemical expression of phosphorylated-ErbB3 (pErbB3) receptor 
and the mutational status of KRAS, EGFR and ALK genes. 
The NRG1 rearrangements were detected in 31% IMAs and 3% non-IMAs and 
the CD74-NRG1 fusion transcript variant was characterized in 4 NRG1-positive IMAs. 
Moreover, pErbB3 expression was found to be strictly associated to the mucinous 
pattern (p = 0.012, Chi-square test) and all IMA cases showing aberrant expression 
of pErbB3 demonstrated NRG1 rearrangements. No significant correlation between 
NRG1 rearrangements and EGFR, KRAS or ALK mutations respectively, was observed.
We report for the first time that NRG1 fusions are driver alterations clearly 
associated with mucinous lung adenocarcinoma subtype of Caucasian patients and 
not exclusive of Asiatic population. pErbB3 immunostaining may represent a strong 
predictor of NRG1 fusions, pointing out the detection of pErbB3 by IHC as a rapid and 
effective pre-screening method to select the NRG1-positive patients.
                                                       Research Paper
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INTRODUCTION
The aberrant activation of members of the family of 
epidermal growth factor receptor tyrosine kinases (EGFR/
ERBB) has been implicated in cancer development and 
progression. In lung cancer, mutations of epidermal growth 
factor receptor (EGFR) are a predictive marker of response 
to tyrosine kinase inhibitors (TKIs). The overexpression of 
ErbB3 receptor is a marker of acquired resistance of lung 
cancer to gefitinib and lapatinib [1–3], and is related to 
HER2 and MET genes point mutations or amplifications 
[4]. In the last years, the deregulation of ErbB2/ErbB3 
machinery  is also emerging as an oncogenic trait of lung 
adenocarcinoma with mucinous pattern,  a tumor subtype 
that is otherwise associated with KRAS mutations [5]. ALK 
positive lung adenocarcinomas often exhibit mucinous 
features, although these are usually morphologically 
distinct from classic mucinous adenocarcinoma [6]. 
Mucinous lung adenocarcinoma accounts for 2% to 
5% of all lung adenocarcinomas and is characterized 
by a unfavorable clinical course and/or for which no 
effective treatment exists [7, 8]. The chimeric CD74-
NRG1 (Cluster of Differentiation 74-Neuregulin-1) gene 
derived by the chromosome 8 rearrangement is recently 
reported as the first potentially treatable oncogenic driver 
alteration associated with this specific pattern of lung 
adenocarcinoma. NRG1 rearrangements accounted for 
a large portion of Invasive Mucinous Adenocarcinoma 
(IMA) of the lung [9] of Asian patients, both in KRAS-wild 
type and KRAS mutated tumors. However, it is of note that 
quite all the just published study cohorts were from Asian 
population. Only three Caucasian cases of IMA have been 
investigated for NRG1 rearrangements by fluorescent in 
situ hybridization (FISH) and resulted negative [10]. 
The chimeric NRG1 transcripts enhance the 
ectopic expression of the neuronal NRG1 III-β3 isoform, 
one of ErbB3 ligands, and induce the phosphorylation 
of the kinase domain of ErbB3 receptor and its 
heterodimerization with ErbB2. The consequent aberrant 
tyrosine kinase activity results in tumorigenesis via 
PI3K–AKT and MAPK pathways. Interestingly, the 
immunohistochemical expression of phospho-ErbB3 
(pErbB3) has been occasionally reported to be associated 
with NRG1 fusion-positive cases [9]. Such finding 
strongly suggests that pErbB3 immunostaining could 
represent an easy indirect approach to identify cancers 
carrying a NRG1 fusion. 
The aim of this study was to assess the prevalence of 
NRG1 rearrangements in a Caucasian population of lung 
cancer patients, and verify the hypothesis that pErbB3 IHC 
overexpression is a predictive marker of NRG1 fusions. 
We analyzed a cohort of 85 formalin-fixed paraffin-
embedded (FFPE) IMA and non-IMA lung cancers from 
Italian patients by combining pErbB3 IHC and NRG1 
status assessed by FISH. Results were correlated with 
KRAS, EGFR and ALK genetic alterations.
RESULTS
pErbB3 expression in primary lung 
adenocarcinoma
Selective IHC was performed by staining 
representative tumor tissue sections of all 85 cases using 
a specific pErbB3 antibody (clone pTyr1289). Mainly a 
membranous, and/or cytoplasmic positivity for pErbB3 
antibody was observed; only in two cases a nuclear pattern 
was noticed (Figure 1). An unambiguous difference in 
pErbB3 expression between IMA versus non-IMA group 
was found. More specifically, 15/51 (29%) IMA and 
3/34 (9%) non-IMA samples cases resulted positive for 
pErbB3. Moreover, pErbB3 expression was found to be 
strictly associated to the mucinous pattern in a statistically 
significant manner (p = 0.012, Chi-square test). 
NRG1 rearrangement identification by 
Fluorescent In Situ Hybridization (FISH) 
analysis
NRG1 rearrangements were assessed by FISH using 
two different probe sets: two BACs (Bacterial Artificial 
Chromosomes) hybridizing on 5′ and 3′ of the NRG1 
gene (RP11-715M18 and RP11-15H14), and custom 
fluorescent oligo-probes (Agilent Technologies) designed 
on flanking regions of NRG1 (5′-Red ID0716491 and 
3′-Green ID0716501 probes) (Figure 2). Both BAC and 
oligonucleotide probe sets were validated using MB-MD-
175-VII cell line that carries NRG1 rearrangement [11]. 
The interpretation of FISH signals followed the same 
criteria used for ALK and ROS1 rearrangements in non 
small cell lung cancers [12, 13]. Briefly, samples were 
considered positive if at least 15% (of a minimum of 50 
valuable nuclei) of cells showed split NRG1 5′ and 3′ 
probe signals or isolated 3′ signals. The distance between 
two separated signals was estimated using twice the size of 
the biggest signal size. As results, NRG1 rearrangements 
were found in 16 of 51 (31%) IMA and only 1 of 34 (3%) 
non-IMA cases (Figure 3). The mean range of rearranged-
positive cell rate in the NRG1-rearranged groups were 
30% (range 18–55%). Both split signals and single 3’ 
signals were observed indicating the co-occurring deletion 
of 5′ portion of NRG1 gene and the number of split was 
more higher than isolated 3′ signals. 
NRG1 fusion transcript characterization 
Genetic rearrangements does not necessarily 
prove expression of a fusion gene, so we searched for 
the presence of an NRG1 transcript fusion in the FISH 
positive samples. We screened by RNA target sequencing 
4 NRG1 FISH-positive IMAs for which the RNA from 
FFPE was available. We used a customized RNA-seq 
panel to target the described fusion transcripts of NRG1 
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gene CD74(Ex6)-NRG1(Ex6), CD74(Ex8)-NRG1(Ex6), 
SLC3A2(Ex5)-NRG1(Ex6)). All four cases expressed 
the same CD74(Ex6)-NRG1(Ex6) fusion variant. As 
consequence of the rearrangement, an active chimeric 
ligand is predicted to be generated, which retains the Nrg1 
βIII membrane-tethered EGF-like domain, as previously 
described (Figure 2). 
Correlation analysis between the presence of 
NRG1 rearrangement detected by FISH and 
immunopositivity of pErbB3 
NRG1 rearrangements were reported to produce an 
increase in the fusion transcript and chimeric ligand that 
aberrantly induces ErbB2/ErbB3 heterodimerization and 
ErbB3 receptor activation by phosphorylation. So, we 
expected to obtain a positive IHC results using an antibody 
against pErbB3 in tissue tumor samples where a functional 
NRG1 rearrangement occurs. 
In line to this hypothesis, results from pErbB3 
immunostaining performed on all 85 FFPE lung cancer 
samples (51 IMAs and 34 non-IMAs) were correlated with 
the presence of NRG1 rearrangements assessed by FISH. 
As results, of the 16 IMAs with NRG1 rearrangement, 
15 resulted pErbB3 positive and only one was negative, 
suggesting a sensitivity of 100% and a specificity of 97% 
of the indirect IHC immunohistochemical assay (Figure 3).
All adenocarcinomas with the NRG1 fusions 
showed an increased expression of pErbB3 in tumor cells 
compared to the adjacent normal bronchial epithelium 
in which a basal level staining of the protein was 
demonstrated. Details were observed for the MD-10 and 
LCCH-584 cases. In the first one, the NRG1 rearrangement 
was identified in 47% of pErbB3-positive area and in 10% 
of pErbB3-negative area. In MD-10 lung tissue, the NRG1 
rearrangement was found in 55% of IHC-positive area and 
in 4% of IHC-negative area.
Correlation of NRG1 fusions with other 
molecular lesions of lung IMAs
The assessment of EGFR and KRAS mutations in 
the cohort is reported in Supplementary Table 4. KRAS 
mutations were more frequent in IMAs (18/46, 39%) than 
in non-IMAs (5/32, 16%) cases. Specific KRAS mutations 
observed in the IMAs included 7 G12D, 4 G12C, 3 G12V, 
2 G12A and 1 G13D, whereas in non-IMAs 3 G12C, 1 
G12V and 1 G12D were detected. 
Interestingly, 6 of the 18 IMAs having a KRAS mutation 
also harbored the NRG1 rearrangement (33%). All IMA cases 
were negative for EGFR mutations whereas exclusively 3 
non-IMA cases resulted EGFR mutated. ALK rearrangement 
was detected just in one non-mucinous adenocarcinoma (data 
not shown) without coexisting NRG1 fusions.    
Figure 1: Microphotograph show mainly a membranous, and/or cytoplasmic positivity for pErbB3 antibody in IMA 
(A–B). Nuclear pattern respectively in IMA (B) and non-IMA (C) can be also observed.
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No significant correlation was observed between 
the presence of NRG1 rearrangements or pErbB3 
immunopositivity and KRAS mutations, patients’ age, 
gender, or tumor stage. 
DISCUSSION 
The results of our study can be summarized 
as follows: i) NRG1 rearrangements are firstly well 
described in a cohort of Caucasian lung adenocarcinoma 
patients and represent a feature of pulmonary IMA; ii) 
prevalence of NRG1 fusions in Caucasian patients is 
similar to that reported in Asian population; iii) pErbB3 
immunostaining is a strong predictor of NRG1 fusions; iv) 
NRG1 rearrangements are not mutually exclusive to KRAS 
mutations in IMAs also in Caucasian patients.
NRG1 fusion genes in lung adenocarcinoma 
have been reported for the first time in 4 of 15 (27%) 
Asiatic IMAs [9]. Very few other studies confirmed this 
finding, but exclusively on Asian cohorts, and reported 
Figure 2: (A) Nuclei MD-175. (B) Schematic illustration of FISH probes map used for detection of NRG1 rearrangement. For break-apart 
FISH assay telomeric BAC RP11-715M18 (chr8:32,264,921-32,433,449) and centromeric RP11-15H14 (chr8:32,679,447-32,840,717) 
were co-hybridized. Further FISH tests were performed by use of custom 5′-Red ID 0716491 (~450 Kb) and 3’-Green ID 0716501 (~450 
Kb) probes. NRG1 gene, BACs and custom probes are represented not in scale. (C) IMA (case MD-55) showing p-ErbB3 immunoreactivity. 
Magnification X20. (D) FISH analysis of case MD-55 shows disrupted NRG1 locus. Red arrows highlight the split of the green and red 
probe signals (hybridizing to 3′ and 5′ regions of NRG1 respectively). (E) IMA (case LCCH-556) without p-ErbB3 immunoreactivity. 
Magnification X20. (F) FISH analysis of case LCCH-556 shows the wild-type NRG1 locus. 
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a prevalence of NRG1 fusions ranging from 8% to 27% 
[14–16]. Only 3 Caucasian IMA cases were analyzed 
to date, but NRG1 rearrangements were not detected by 
FISH (Table 1) [10]. Our finding of a 31% (16/51 cases) 
prevalence of NRG1 rearrangements in the largest cohort 
of Caucasian lung IMAs analyzed to date is the first 
extensive analysis reported and overlaps the prevalence 
described in Asian lung cancer patients. These data 
support a link between NRG1 fusions and lung mucinous 
adenocarcinoma, regardless of ethnical or geographical 
origin. However, we found that the NRG1 fusion is not 
exclusive of mucinous lung adenocarcinomas but it can be 
also found with a very lower prevalence (3%) in non-IMA 
lung population. Similarly to the other lung cancer gene 
fusions, we firstly reported NRG1 rearrangement patterns 
in form of isolated 3′ signals, thus indicating a strength 
analogy with ALK and ROS1 fusions, where a 5′ gene 
deletion was frequently observed.  
Our RNA sequencing of four NRG1 rearranged IMA 
cases identified the same CD74-NRG1 chimeric transcript, 
thus corroborating our FISH results. Indeed, CD74 has 
been reported as the most frequent NRG1 fusion partner, 
but SLC3A2, VAMP2, RBPMS, WNR and SDC4 may 
be alternative 5′ partners of the chimeric gene [16–18]. 
All these NRG1 fusions are predicted to retain the EGF-
like domain of the wild-type NRG1 III-β3 isoform.  The 
free active NRG1 chimeric ligands in the extracellular 
spaces bind their the pErbB3 receptor in an autocrine or 
paracrine fashion and produces oncogenic signals through 
ErbB2-ErbB3 heterodimers that leads to phosphorylation 
of ErbB3 [9]. We thus hypothesized that the expression 
of phosphorylated ErbB3 could be a potential marker of 
NRG1 fusion genes. 
Our data show that the expression of pErbB3 as 
detected by immunohistochemistry is a feature of one 
third (16/51, 31%) of the IMA subtype of lung cancer 
Figure 3: Flow chart of the study and summary of results. IMA, invasive mucinous adenocarcinoma. White boxes, type and 
number of cases. Yellow boxes, analysis performed. Green boxes, positive results. Grey boxes, negative results.
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(p = 0.002, Chi-square test). On immunohistochemical 
analysis, pErbB3 was found localized mainly in the cell 
membrane and cytoplasm of tumor cells and only in two 
cases in the nucleus. There are few studies regarding the 
localization of pErbB3. These studies suggest that ErbB3 
localized in the cell membrane translocates partially to the 
nucleus via ligand stimulation where it targets a particular 
gene to induce the expression of specific oncoproteins 
[19]. Of particular interest, we found that the genomic 
rearrangements of NRG1 were identified by FISH analysis 
in all the 15 IMA pErbB3 immunopositive cases and in 
one of three non-IMA pErbB3 immunopositive cases. 
Notably, a NRG1 rearrangement was found in only one of 
the 36 pErbB3 immunonegative IMAs. 
These data suggest a high sensitivity and specificity 
of pErbB3 immunoreactivity as a strong predictor of 
NRG1 fusion genes identified by FISH analysis on FFPE 
tissues. To date, NRG1 fusions were identified quite 
exclusively by RNA sequencing and just in one case 
confirmed by FISH analysis. No pre-selection by p-ErbB3 
overexpression was reported in any studies. Our approach 
should be much more user-friendly compared to a Next 
Generation Sequencing due to the high costs and the 
quality of samples required for this type of analysis. 
Finally, taking into account the prevalence of 
KRAS mutations in the lung mucinous subtypes [20], 
we investigated the relationship between NRG1 fusion 
and KRAS mutations. Although it has been suggested 
that these two lesions could be mutually exclusive each 
other in IMAs [9, 14], either our data in Caucasian 
patients and those reported by Shin et al. in Korean 
patients [16] refuted this hypothesis (see Table 2). We 
found that six of the 16 tumors showing NRG1 fusion 
also harbored a mutations in KRAS gene, proposing 
an heterozygous nature of the fusion alleles in these 
samples and also declining the previous reported 
suggestion to use the presence of KRAS mutations as 
an exclusion criteria to perform FISH analysis at NRG1 
locus [10]. NRG1 fusion coexisting with EGFR or ALK 
fusion were not identified. 
The translational impact of the NRG1 fusions 
arises from the following recently published functional 
investigations. It has been shown that cancer cells 
harboring NRG1 fusions overexpress the EGF-like 
domain of NRG1 III-β3 as a critical step for lung cancer 
tumorigenesis [9, 14, 16–18]. The expression of CD74-
NRG1 fusion gene is able to promote cancer stem cell 
properties and it is involved in stem cell function of several 
types of cancers, including lung cancer. This data implies 
the existence of a mechanism by which the activated ErbB 
receptors contribute to the acquisition of CSC (Cancer 
Stem Cell)-like characteristics together with the ability 
of cancer cells to develop a resistance to chemotherapy 
[21]. Of interest, NRG1 fusions have been proved to be 
coexistent with ALK fusion or RAS mutation in NSCLC 
patients both in primary and in metastatic sites of lung 
tumors [19, 22, 23] and it has been recently considered 
as a potential mechanism of resistance after treatment 
with crizotinib in ALK-rearranged NSCLC cell lines [24]. 
This assumption has been further confirmed showing that, 
under treatment with second-generation ALK inhibitors, 
NSCLC cells activated the EGFR family pathways 
directly through the NRG1-ErbB3-EGFR activation axis 
[25]. In support to these in vitro reports, the onset of the 
SLC3A2-NRG1 gene fusion during the natural history of 
two invasive mucinous lung adenocarcinoma in Asiatic 
patients has been described. These heavily pre-treated 
patients received the combination of lumretuzumab, a 
monoclonal anti-ErbB3 antibody, plus erlotinib, an anti-
EGFR small molecule, showing tumor shrinkage [26]. 
The aberrant tyrosine kinase activity of ErbB2/
ErbB3 receptors caused by NRG1 fusions represent an 
opportunity for the development of new anticancer drugs 
acting through inhibition of the ErbB network. This has 
already been shown to be a successful approach with EGFR 
and ErbB2 inhibitors [27–28]. To date, ErbB3 specific up-
Table 1: Prevalence of NRG1 fusions reported in invasive mucinous adenocarcinomas of  the lung
Study (References) Ethnicity NRG1-fusion* KRAS mutation
KRAS mutation
plus NRG1 fusion Tissue
Fernandez-Cuesta et al. 
(2014) Asian (Japan) 4/15 (27%) 6/15 (40%) 0/4 (0%) frozen
Gow et al. (2014) Asian (Taiwan) 1/13 (8%) 3/12 (25%) 0/1 (0%) frozen
Nakaoku et al. (2014) Asian (Japan) 6/90 (7%) 56/90 (62%) 0/6 (0%) frozen
Shin et al. (2016) Asian (Korea) 16/59 (27%) 29/59 (49%) 10/16 (62%) frozen
Duruisseaux et al. (2016)
Caucasian (3) 
Asian (1)
North African (1)
1/5 (20%)a 0/5 (0%) 0/5 (0%) FFPE
This Study Caucasian (Italy) 16/51 (31%) 18/46 (39%) 5/46 (11%) FFPE
*The prevalence of NRG1 fusions is calculated on the effective number of IMAs evaluated for this aberration.
aThe case showing NRG1 rearrangement was Asian (Vietnamese).
FFPE, formalin-fixed paraffin-embedded.
Oncotarget9667www.impactjournals.com/oncotarget
regulation has not been yet targeted by drugs showing a 
clear clinical activity. Monoclonal antibodies that target 
different sites of ErbB2 and ErbB3 domains and block the 
heterodimerization process are actually under evaluation 
[29]. Many of these clinical trials are biomarker-selected 
randomized studies that involve lung cancer patients and 
assess exclusively the status of ErbB2 receptor by mutation 
screening or immunohistochemistry (NCT01827267, 
NCT02289833, NCT02387216). As NRG1 fusions induce 
the dimerization of ErbB3 receptor, and may thus represent 
a useful additional molecular marker to stratify patients and 
test the efficacy of these compounds. 
In conclusion, our study documents that NRG1 
fusions are a feature of a subgroup of IMA of the lung, 
regardless of ethnicity of patients, and gives for the first 
time a clear evidence of a strong association between 
pErbB3 expression and NRG1 fusions. This genomic 
alteration may represent a unique therapeutic opportunity 
to test the efficacy of compounds designed to inhibit ErbB 
network activity in this subset of IMA of the lung.
MATERIALS AND METHODS
Cell lines
MB-MD-175-VII breast cancer and H1993 lung cancer 
cell lines were purchased from the American Type Culture 
Collection (ATCC) and were cultivated at 37°C in DMEM/
F12 and RPMI 1640 medium respectively, supplemented 
with 10% FBS and 1% penicillin and streptomycin.
Patients and tissue samples
A total of 85 primary lung adenocarcinoma from 
Caucasian Italian patients (51 IMAs and 34 non-IMAs) 
were collected from 2002 to 2015 at the IRCCS “Casa 
Sollievo della Sofferenza” in San Giovanni Rotondo and 
IRCCS Arcispedale Santa Maria Nuova in Reggio Emilia as 
formalin fixed paraffin embedded (FFPE) blocks (Table 2). 
The mean patient’s age at the time of diagnosis was 65 
± 9 (mean ± SD) with a range from 38 to 84 years. More than 
half of the patients were men (64%) versus 36% of women. 
All patients underwent curative surgery and all tumors were 
evaluated by two expert pulmonary pathologists (GR and 
PG) and classified as non-IMA and IMA according to the 
current WHO classification [30]. Representative blocks of 
the each neoplasm were selected for immunohistochemical 
and molecular studies. Materials and associated demographic 
and clinical information were collected according to the 
Local Ethics Committee approval (prot. 08/CE-52/CE 
IRCCS Casa Sollievo della Sofferenza. Prot. 2013/0026784 
IRCCS Arcispedale Santa Maria Nuova in Reggio Emilia).
Immunohistochemical analysis 
Each lung cancer was characterized using the routinely 
diagnostic panel of antibodies reported in Supplementary 
Table 1 by an automated immunostainer (Benchmark XT, 
Ventana Medical System). Immunohistochemical expression 
of pErbB3 (clone Tyr1289, Cell Signaling) was performed 
on Autostainer Link 48 (Dako, Agilent) and FFPE cell 
pellets from the H1993 cell lines and tissue sections from 
breast cancers were used as positive controls. Briefly, after 
antigen retrieval in Tris-EDTA buffer (0.01 M) at 98°C, as 
indicated by the manufacturer, 3 µm FFPE tumor sections 
were incubated with hydrogen peroxide (0.3% v/v) in 
methanol for quenching endogenous peroxidase activity 
and thereafter incubated with primary antibody for 45 min 
at room temperature. The reaction was revealed using the 
EnVisionTMFLEX+ detection kit (Dako, Agilent). The 
sections were counterstained with Mayer’s hematoxylin 
and mounted with Biomount (BIO-OPTICA). As negative 
control, the primary antibody was replaced by isotype 
specific non-immune rabbit IgG.
After independent observation by two expert 
pathologists (GR and PG), pErbB3 protein expression was 
defined as positive if at least 10% of lung adenocarcinoma 
cells showed moderate or strong membrane and/or 
cytoplasmic reactivity [31].
DNA and RNA extraction
Unstained FFPE cancer tissue sections (10µm 
thick) were microdissected to enrich for at least 60% 
cancer cells. DNA was extracted using the GeneRead 
DNA FFPE kit (Qiagen) and quantified with the Qubit 
dsDNA BR assay Kit (Life Technologies). DNA from cell 
lines was prepared using a standard Phenol-Chloroform 
procedure. Total RNA from FFPE sections was purified 
with the RecoverAll™ Total Nucleic Acid Isolation kit 
(Ambion). RNA from cell lines was extracted using Trizol 
Reagent (Life Technologies). The quality and quantity of 
the RNA was assessed using the Qubit RNA BR assay 
(Life Technologies).
Fluorescence in situ hybridization (FISH) analysis
Structural rearrangements of NRG1 gene (Chr 8p12) 
were assessed by FISH analysis with two different probe 
sets for break-apart assay: BAC and Oligonucleotide 
probe sets designed on flanking regions of the NRG1 
gene. BACs were selected according to the February 2009 
release of GRCh37/hg19 by the University of California 
at Santa Cruz Human Genome Browser (http://genome.
ucsc.edu), and were RP11-715M18 (chr8: 32,264,921-
32,433,449) and RP11-15H14 (chr8: 32,679,447-
32,840,717), encompassing the 5′-NRG1 and 3′-NRG1 
respectively. The set of Oligonucleotide probes were 
designed (5’-Red ID0716491 and 3’-Green ID0716501 
probes) using the Agilent Sure Design software (https://
earray.chem.agilent.com/suredesign).
Three µm FFPE sections were hybridized with 
BAC probes labeled by nick translation. Briefly, 600 ng 
of labeled probes were used; hybridization was performed 
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at 37°C in 2× saline-sodium citrate (SSC), 50% (vol/
vol) formamide, 10% (wt/vol) dextran sulfate, 5 μg 
Cot-1 DNA (Bethesda Research Laboratories), and 3 
μg sonicated salmon sperm DNA in a volume of 10 μl. 
Post-hybridization washings were at 73°C in 2× SSC 
for 2 min, followed by three washes in 2x SSC at room 
temperature. Nuclei were stained by 4,6-diamidino-
2-phenylindole (DAPI). The hybridized slides 
were viewed on an Olympus IX-50 epifluorescence 
microscope (Olympus) equipped with a cooled CCD 
camera (Princeton Instruments) at 100X magnification 
with oil immersion. The GenASIs software (Applied 
Spectral Imaging, Carlsbad, CA, USA) was used to 
generate multicolor images. FISH with Agilent custom 
oligonucleotide probes were performed according to the 
manufacturer’s protocol. NRG1 fusion rate was assessed 
by scoring all evaluable nuclei, in both pErbB3 positive 
and negative staining regions of the section. A minimum 
of 50 non-overlapping tumor cells with at least two each 
of 5′ and 3′ signals were examined for each case. Similar 
to ALK and ROS1 FISH guidelines, the rearrangement-
positive cells were defined as those with split signals or 
isolated red (3′) signals with a frequency ≥ 15%  of the 
enumerated tumor cells.
Table 2: Clinical and pathological features of lung adenocarcinoma patients enrolled for the study 
(n = 85)
Characteristics n (%)
Age at diagnosis (mean ± SD) 65 ± 9
Sex
M 53 (64%)
F 32 (36%)
Adenocarcinoma subtype
Mucinous 51 (60%)
non-mucinous 34 (40%)
Tumour Stage (pT)
1a 16 (19%)
1b 12 (14%)
2a 20 (24%)
2b 13 (15%)
3 11 (13%)
4 6 (7%)
x 7 (8%)
Lymph nodes stage (pN)
0 75 (88%)
1 3 (4%)
x  7 (8%)
Metastasis stage  (pM)
M0 71 (84%)
M1 5 (6%)
x 9 (10%)
UICC Stage
IA 26 (31%)
IB 19 (22%)
IIA 13 (15%)
IIB 11 (13%)
IIIA 3 (4%)
IIIB 0 (0%)
IV 5 (6%)
Missed 8 (9%)
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KRAS, EGFR and ALK mutations
DNA from lung cancers was analyzed for the 
KRAS and EGFR gene by Sanger sequencing and ddPCR 
(Supplementary Table 2). For Sanger sequencing, 50 
ng of genomic DNA were amplified with appropriate 
primers, PCR products were purified using GFX PCR 
DNA and Gel Band Purification Kit (GE Healthcare). 
Sequencing reactions were performed using 5 ng of PCR 
products and Big Dye Terminator Ready Reaction mix v. 
1.1 (Thermo Fisher),  loaded on an ABI 3100 sequence 
detection system (Thermo Fisher) and analyzed using 
the Sequencing Analysis software v.3.7 (Thermo Fisher). 
Digital droplet PCR was performed using QX100™ 
Droplet Digital™ PCR System (Bio-Rad) and appropriate 
primers and probes for KRAS and EGFR mutations (www.
bio-rad.com/it). Droplets were generated using a Droplet 
Generator and then amplified in a C1000 Touch™ deep-
well Thermal Cycler (Bio-Rad). After cycling, the 96-
well plate was placed into the QX200 Droplet Reader 
(Bio-Rad) where droplets of each sample are analyzed 
sequentially and fluorescent signals of each droplet 
are measured individually by a detector. Data were 
analyzed with Quanta Soft analysis software, version 
1.7.4. Anaplastic lymphoma kinase (ALK) gene status 
was determined by immunohistochemical analysis using 
anti-ALK antibody (clone D5F3, Cell Signaling). All the 
adenocarcinomas showing cytoplasmic with /without 
membrane immunoreactivity were defined as ALK 
positive. The cases displaying weak (score 1) or moderate 
(score 2) ALK staining were also evaluated by FISH 
analysis. Adenocarcinomas demonstrating strong (3+) 
ALK immunoreactivity were defined as ALK rearranged.  
Fusion Transcript identification by RNA Target 
Sequencing 
Total RNA (50 ng) was reverse transcribed using the 
SuperScript VILO cDNA Synthesis Kit followed by library 
generation using the Ion AmpliSeq Library Kit 2.0 and a 
Custom Ion AmpliSeq RNA Fusion Panel (ID IAD107474, 
Thermo Fisher Scientific) designed to target the 
described fusion transcripts of NRG1 gene (CD74(Ex6)-
NRG1(Ex6), CD74(Ex8)-NRG1(Ex6), SLC3A2(Ex5)-
NRG1(Ex6)), additional 103 fusion transcripts and 12 
housekeeping genes (MYC, TBP, JUN, CFHR5, AFM, 
LMNA, MRPL13, MTTP, ITGB7, HBMS, APOB, LRP1) 
as internal positive controls (Supplementary Table 3). 
Barcodes were added during library generation using the 
IonXpress Barcode Adapters. Libraries were quantified 
using the 2100 BioAnalyzer (Agilent Technologies), then 
pooled in equimolar concentrations. The library pool was 
templated using the Ion PGM Hi-Q Chef Kit on the Ion 
Chef and sequenced using an Ion 318 chip on the Ion 
Torrent PGM™ sequencer (Thermo Fisher Scientific). 
After sequencing, data were automatically transferred 
and analyzed on the Ion Reporter Server (Thermo Fisher 
Scientific) using the “single fusion” workflow in order to 
detect and annotate variants in NRG1 fusion transcripts. 
This workflow aligns and counts reads matching with 
the target transcripts, taking into account only reads that 
overlap the theoretical target by more than 70%. Counts 
are normalized to the total number of mapped reads and 
expressed in reads per million.
Statistical analysis
Study sample size was not calculated according to a 
pre-defined hypothesis, because the study was conducted 
with an explorative aim, in the absence of enough data 
available in the literature. Patients baseline characteristics 
have been reported as mean ± standard deviation (SD) 
or median ± range for continuous variables, and as 
frequencies and percentages for categorical variables. 
NRG1, pErbB3 and KRAS status was compared between 
groups using Pearson Chi-square and Fisher’s exact tests, 
as appropriate. 
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